NASDAQ$ANNX
Annexon Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Annexon reported fourth quarter and full-year 2020 financial results and business highlights.
Annexon reported a net loss of $23.2 million for the quarter ended December 31, 2020, compared to a net loss of $8.9 million for the quarter ended December 31, 2019. The company's cash and cash equivalents and short-term investments were $351.2 million as of December 31, 2020.
- Completed evaluation of drug-drug interaction study of ANX005 co-administered with Intravenous Immunoglobulin (IVIg) in 14 patients with GBS.
- Initiated a Phase 2 trial evaluating the efficacy of ANX007 in reducing the area of GA in patients with GA.
- Appointed William H. Carson, M.D. to the Board of Directors.
- Thomas G. Wiggans was appointed as Annexon’s chairman.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$0
Forward guidance
Annexon is rapidly advancing multiple Phase 2 clinical programs across a diverse set of potential indications, and accelerating development of a number of innovative, next generation product candidates. This clinical momentum coupled with our strong capital position positions us well to drive value in 2021 and beyond.
Tailwinds
- Advancement of the company’s clinical and preclinical programs
- Timing of data from clinical trials and submission of data to peer-reviewed forums
- Confidence in the company’s product candidates
- The company’s ability to drive value in 2021 and beyond
- Implementation of the company’s business model and strategic plans for its business and product candidates, including potential treatment indications and additional indications that the company may pursue
Headwinds
- The company’s history of net operating losses
- The company’s ability to obtain necessary capital to fund its clinical programs
- The early stages of clinical development of the company’s product candidates
- The effects of COVID-19 or other public health crises on the company’s clinical programs and business operations
- The company’s ability to obtain regulatory approval of and successfully commercialize its product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro